Skip to main content
. 2022 Aug 27;13(3):942–954. doi: 10.1016/j.apsb.2022.08.015

Figure 4.

Figure 4

Immune activity of DOTAP/CHOL-mRNA, DOTAP-mRNA and SA@DOTAP-mRNA in vitro and in vivo. (A) Antigen presentation of DOTAP/CHOL-OVA, DOTAP-OVA and SA@DOTAP-OVA in BMDCs. (B) The in vivo expression of luciferase in mice after intravenous injection with DOTAP/CHOL-LUC, DOTAP-LUC and SA@DOTAP-LUC. (C) Quantitative analysis of luciferase expression in the spleens of mice treated by DOTAP/CHOL-LUC, DOTAP-LUC and SA@DOTAP-LUC, respectively. (D, E) FACS analysis of OVA-specific CTL proliferation in the spleen. Data are presented as mean ± SD (n = 3). ∗∗∗P < 0.01.